Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators are the first drugs to directly target the underlying defect of the disease, and have been transforming treatment of people with Cystic Fibrosis (pwCF). The combination of elexacaftor-tezacaftor-ivacaftor (ETI) is the newest and most effective CFTR modulating medicine [1]. ETI is administered at a fixed dose in adolescents and adults (aged 12 years and older) and adjusted to age and/or weight in the pediatric population (under 12 years) [1].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research